Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 6/28/17 (What's New)

Summary

  • Maintenance of undetectable HBV DNA levels is the key on-treatment goal in nucleos(t)ide analogue–treated patients
    • In HBeAg-positive patients, the definitive endpoint for therapy is HBeAg seroconversion. Treatment may be discontinued in patients without cirrhosis who have achieved this endpoint and completed ≥ 12 months of consolidation therapy after the appearance of anti-HBe (Table 8)[Terrault 2016]

      • AASLD recommends indefinite treatment for patients with cirrhosis[Terrault 2016]

Action required